FIGURE 1



120
100
80
60
40
20
0
% of control
VC8
VC8-B2
0
0.1
0.2
0.3
0.4
0.5
0.6
Doxorubicin (μM)

FIGURE 2



120
100
80
60
40
20
0
Proliferation (% of control)
VC8
VC8 restored BRCA2
0
0.5
1
1.5
2
uM SNS-595

FIGURE 3



100
10
1
0.1
0
2
4
6
8
Colony outgrowth (% of control)
Doxorubicin (nM)
U2OS
U2OS
+siBRCA2

FIGURE 4



100
10
1
0.1
Colony outgrowth (% of control)
U2OS
U2OS +siBRCA2
0
50
100
150
200
SNS-595 (nM)

FIGURE 5



marker
untreated
Aphidicolin
Doxorubicin
Doxorubicin + Aphidicolin
SNS-595
SNS-595 + Aphicolin
DNA size (Mbp)
2.2
1.6
1.1
0.8
0.6
0.5

FIGURE 6



marker
untreated
Aphidicolin
Doxorubicin
Doxorubicin + Aphidicolin
SNS-595
SNS-595 + Aphicolin
50 Gy
DNA size (Mbp)
2.2
1.6
1.1
1.0
0.83
0.68
0.61
0.45
0.37
0.29
0.23

FIGURE 7



10
1
0.1
0.01
Intensity of photo stimulated luminiscence (arbitrary units)
Undamaged DNA
Damaged DNA
Doxorubicin
SNS-595
15Gy
2.2
1.6
1.1
0.8
0.6
0.4
0.2

FIGURE 8



Undamaged DNA
Damaged DNA
Doxorubicin
SNS-595
50Gy
Intensity of photo stimulated luminescence (arbitrary units
1
0.1
0.01
2.2
1.6
1.1
0.8
0.6
0.4
0.2

FIGURE 9




cloning efficiency (% of control)
180
160
140
120
100
80
60
40
20
0
untreated
Aphidcolin
Doxorubicin
Doxorubicin+Aph
SNS-595
SNS-595 + Aph

FIGURE 10


reversion frequency (/10^5 cells )
14
12
10
8
6
4
2
0
untreated
Aphidcolin
Doxorubicin
Doxorubicin+Aph
SNS-595
SNS-595 + Aph